Investigating how cell interactions and environment affect liver disease
Synergistic effects of ECM and heterotypic crosstalk on cellular responses in non-alcoholic fatty liver disease
['FUNDING_R01'] · UNIVERSITY OF ILLINOIS AT CHICAGO · NIH-10872177
This study is looking at how liver cells talk to each other and react to their surroundings in people with non-alcoholic steatohepatitis (NASH), with the hope of finding new treatments that could help improve liver health.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ILLINOIS AT CHICAGO (nih funded) |
| Locations | 1 site (Chicago, UNITED STATES) |
| Trial ID | NIH-10872177 on ClinicalTrials.gov |
What this research studies
This research focuses on non-alcoholic steatohepatitis (NASH), a serious liver condition that can lead to severe complications. It aims to understand how different types of liver cells communicate and how their environment influences their behavior, particularly in the context of fibrosis. By using engineered culture systems that mimic the liver's microenvironment, the study seeks to uncover the mechanisms that drive liver cell changes and identify potential new treatments. Patients may benefit from insights gained through this research that could lead to more effective therapies for liver disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-alcoholic steatohepatitis (NASH) or those at risk of developing liver fibrosis.
Not a fit: Patients with liver diseases caused by alcohol consumption or other non-NASH related conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel therapies for patients suffering from non-alcoholic fatty liver disease.
How similar studies have performed: Previous research has shown promise in understanding liver disease mechanisms through similar approaches, but this specific methodology is relatively novel.
Where this research is happening
Chicago, UNITED STATES
- UNIVERSITY OF ILLINOIS AT CHICAGO — Chicago, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KHETANI, SALMAN R — UNIVERSITY OF ILLINOIS AT CHICAGO
- Study coordinator: KHETANI, SALMAN R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.